Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Liabilities: 2016-2025

Historic Total Liabilities for Anaptysbio (ANAB) over the last 9 years, with Sep 2025 value amounting to $382.5 million.

  • Anaptysbio's Total Liabilities fell 6.49% to $382.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $382.5 million, marking a year-over-year decrease of 6.49%. This contributed to the annual value of $413.0 million for FY2024, which is 13.36% up from last year.
  • Latest data reveals that Anaptysbio reported Total Liabilities of $382.5 million as of Q3 2025, which was up 0.67% from $380.0 million recorded in Q2 2025.
  • Anaptysbio's 5-year Total Liabilities high stood at $417.5 million for Q2 2024, and its period low was $14.5 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $380.0 million (2025), whereas its average is $382.6 million.
  • Per our database at Business Quant, Anaptysbio's Total Liabilities crashed by 38.84% in 2021 and then surged by 1,934.02% in 2022.
  • Quarterly analysis of 5 years shows Anaptysbio's Total Liabilities stood at $286.6 million in 2021, then climbed by 21.50% to $348.3 million in 2022, then climbed by 4.60% to $364.3 million in 2023, then climbed by 13.36% to $413.0 million in 2024, then dropped by 6.49% to $382.5 million in 2025.
  • Its Total Liabilities was $382.5 million in Q3 2025, compared to $380.0 million in Q2 2025 and $388.0 million in Q1 2025.